CCX282-B

DRUG3 trials

Sponsors

Amgen

Conditions

Celiac DiseaseCrohn DiseaseCrohn's Disease

Phase 2

Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease

CompletedNCT00102921

AmgenCrohn Disease

Start: 2004-08-31End: 2005-12-31Target: 70Updated: 2025-03-06

A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease

CompletedNCT00306215

AmgenCrohn's Disease

Start: 2006-03-31End: 2009-06-30Updated: 2025-03-06

A Phase II Study of CCX282-B in Patients With Celiac Disease

CompletedNCT00540657

AmgenCeliac Disease

Start: 2007-10-31End: 2008-07-31Target: 90Updated: 2025-03-06

Related Papers

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.

2013-03-20103 citations